Home › Retrophin Signs U.S. License Agreement for Syntocinon Nasal Spray (Oxytocin)
 

Keywords :   


Retrophin Signs U.S. License Agreement for Syntocinon Nasal Spray (Oxytocin)

2013-12-19 08:09:31| dairynetwork News Articles

Retrophin, Inc. recently announced that it has signed an agreement with Novartis Pharma AG for an exclusive U.S. license for Syntocinon™ Nasal Spray, the intranasal formulation of a synthetic version of the naturally occurring peptide hormone oxytocin, for an upfront payment of $5.0 million plus milestone payments and royalties. Syntocinon™ Nasal Spray was approved in the U.S. in 1960 to assist initial postpartum milk ejection, but was discontinued by Novartis in 1997 for

Tags: agreement license signs spray

Category:Agriculture and Forestry

Latest from this category

All news
13.05Join us for the 2024 Global Hog Industry Virtual Conference
13.05Worlds first recipient of a genetically-modified pig kidney dies
13.05Meat prices expected to increase slightly this summer
13.05Meat prices expected to increase slightly this summer
13.05Pennsylvania law aims to protect domestic animals, food supply against disease
13.05Pennsylvania law aims to protect domestic animals, food supply against disease
13.05Ongoing influenza A surveillance critical for U.S. swine herd health
12.05Switzer Ranch staying resilient with long-term outlook
Agriculture and Forestry »
13.05Join us for the 2024 Global Hog Industry Virtual Conference
13.05New version of Chat-GPT can teach maths and flirt
13.05Eastern North Pacific Tropical Weather Outlook
13.05Melinda French Gates to quit Gates Foundation
13.05BASF in South Carolina Joins with Make-A-Wish
13.05PCMC addresses latest printing trends at \'Power Packs Live\'
13.05More than 50 sessions scheduled for drupa cube
13.05IDENTCO highlights automation and PCB labeling at PCB East
More »